How do you convince a brand manager to try a new or unproven approach? Who will be the guinea pig and invest in Web 2.0, or any of the other programs like online sampling and virtual speaker programs? New programs may get a lot of buzz, but implementing them takes a client willing to assume some risk. When a client really needs to focus their resources, we advise them to first do what is tried and true. There is a time for innovation, but there is also a time for doing what you know works.
How do you convince a brand manager to try a new or unproven approach? Who will be the guinea pig and invest in Web 2.0, or any of the other programs like online sampling and virtual speaker programs? New programs may get a lot of buzz, but implementing them takes a client willing to assume some risk. When a client really needs to focus their resources, we advise them to first do what is tried and true. There is a time for innovation, but there is also a time for doing what you know works.
Biopharma's marketing needs are unique in both size and scope. They demand specific knowledge and therapeutic expertise. They require the ability to identify and test smaller, measurable programs, but also must possess the scalability to expand these programs when they prove successful. They need to leverage those marketing programs and vehicles that: target and communicate to/with different target audiences; explain complicated medical and scientific issues; educate clinicians and patients on the proper use of their solutions across different therapeutic areas and, where appropriate, in conjunction with other forms of therapy; provide direct communication to enhance product prescribing and compliance; and extend support and/or augment sales force coverage.
Compass Healthcare Communications is an independent interactive and relationship marketing agency.
Telephone: 609-688-8440
E-mail: contact@compasshc.com
Web site: compasshc.com
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.